Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Enzyme replacement and beyond.

R J Desnick1

  • 1Department of Human Genetics, Mount Sinai School of Medicine of New York University, New York 10029, USA. rjdesnick@mssm.edu

Journal of Inherited Metabolic Disease
|June 19, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Erythropoietic protoporphyria: time to prodrome, the warning signal to exit sun exposure without pain-a patient-reported outcome efficacy measure.

Genetics in medicine : official journal of the American College of Medical Genetics·2021
Same author

Harderoporphyria: Case of lifelong photosensitivity associated with compound heterozygous coproporphyrinogen oxidase (CPOX) mutations.

Molecular genetics and metabolism reports·2019
Same author

Many pitfalls in diagnosis of acute intermittent porphyria: a case report.

BMC research notes·2018
Same author

Exome sequencing of extreme clopidogrel response phenotypes identifies B4GALT2 as a determinant of on-treatment platelet reactivity.

Clinical pharmacology and therapeutics·2016
Same author

X-chromosomal inactivation directly influences the phenotypic manifestation of X-linked protoporphyria.

Clinical genetics·2015
Same author

Extended haplotype association study in Crohn's disease identifies a novel, Ashkenazi Jewish-specific missense mutation in the NF-κB pathway gene, HEATR3.

Genes and immunity·2013
Same journal

Biallelic Loss-Of-Function Variant in ATP5ME Is Associated With Severe and Early Onset Oxidative Phosphorylation Deficiency.

Journal of inherited metabolic disease·2026
Same journal

Beyond Upper Airway Involvement: Evidence of Intrinsic Lung Disease in a Mouse Model of Mucopolysaccharidosis I.

Journal of inherited metabolic disease·2026
Same journal

Immune Dysregulation in Branched Chain Organic Acidemias.

Journal of inherited metabolic disease·2026
Same journal

Long Term Follow-Up After Transplantation in Propionic Acidemia: A Retrospective French Pediatric and Adult Cohort Study.

Journal of inherited metabolic disease·2026
Same journal

Tri-Parametric Assessment of α-Galactosidase A Activity, lysoGb3 and X-Inactivation Aids Genotype-Phenotype Categorization of Fabry Disease Female Patients.

Journal of inherited metabolic disease·2026
Same journal

Mapping the Severity of Phenylalanine Hydroxylase Deficiency.

Journal of inherited metabolic disease·2026
See all related articles

Enzyme replacement therapy is a viable treatment for lysosomal storage diseases like Fabry disease. Clinical trials demonstrate the safety and efficacy of recombinant human alpha-galactosidase A (r-halphaGal A) therapy.

Area of Science:

  • Biochemistry
  • Genetics
  • Pharmacology

Background:

  • Lysosomal storage diseases (LSDs) are a group of inherited metabolic disorders.
  • Enzyme replacement therapy (ERT) has emerged as a successful treatment for some LSDs, notably Gaucher disease.
  • Fabry disease, caused by alpha-galactosidase A (alpha-Gal A) deficiency, is a target for new therapeutic strategies.

Purpose of the Study:

  • To present the drug development process for recombinant human alpha-galactosidase A (r-halphaGal A) as an ERT for Fabry disease.
  • To highlight the regulatory pathways, including orphan drug and fast track designations, that can accelerate therapy development for rare diseases.

Main Methods:

  • Preclinical studies using a 'Fabry mouse' model to evaluate r-halphaGal A.
  • Clinical trials, including Phase 1/2, Phase 3, and Phase 3 extension studies, to assess safety and efficacy.

Related Experiment Videos

  • Regulatory review processes for new drug approvals.

    • Main Results:

    • Preclinical studies in the Fabry mouse model provided a basis for clinical development.
    • Clinical trials demonstrated the safety and efficacy of r-halphaGal A replacement therapy.
    • The drug development process adhered to rigorous regulatory standards.

    Conclusions:

    • Enzyme replacement therapy with r-halphaGal A is a safe and effective treatment for Fabry disease.
    • The development process exemplifies the application of regulatory pathways for rare inherited metabolic diseases.
    • ERT offers a promising therapeutic option for patients with Fabry disease and potentially other LSDs.